Buparlisib (BKM120, NVP-BKM120)

目录号:S2247

Buparlisib (BKM120, NVP-BKM120) Chemical Structure

Molecular Weight(MW): 410.39

Buparlisib (BKM120, NVP-BKM120) 是一种选择性 PI3K 抑制剂,在无细胞试验中作用于p110α/β/δ/γIC50分别为 52 nM/166 nM/116 nM/262 nM。对 VPS34,mTOR,DNAPK 的作用效果下降,而对 PI4Kβ几乎没有活性。Phase 2。

规格 价格 库存 购买数量  
RMB 2227.95 现货
RMB 1400.12 现货
RMB 2607.65 现货
RMB 7928.28 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户购买Selleck的此次产品后发表的文献38篇:

客户使用该产品的6个实验数据:

  • NLGN3 mRNA expression in SU-pcGBM2 cells after 12 hr exposure to vehicle, 50 nM NLGN3, 100 nM BKM120, or 50 nM NLGN3 + 100 nM BKM120.

    Cell, 2017, 161(4):803-16. Buparlisib (BKM120, NVP-BKM120) purchased from Selleck.

    Western blot analysis of cleaved caspase 3 in T cell-enriched PBMCs.

    J Hematol Oncol, 2016, 9(1):113. Buparlisib (BKM120, NVP-BKM120) purchased from Selleck.

  • AN3CA (A) and JHUEM2 (B) cells were treated for the indicated times with DMSO, 0.3 μM BGJ398 (BGJ), 0.3 μM GDC-0941 (GDC), 0.6 μM BYL719 (BYL) and 0.6 μM BKM120 (BKM) alone or in combination. Cell lysates were immunoblotted with antibodies for phospho-AKT (Ser473), total AKT, phospho-ERK (Thr202/Tyr204), ERK2, phospho-S6 (Ser240/244), total S6, phospho-4EBP1 (Thr37/46), total 4EBP1, total PARP and cleaved PARP. Tubulin was detected as the loading control. Western blot analysis of AN3CA and JHUEM2.

    Mol Cancer Ther, 2017, 16(4):637-648. Buparlisib (BKM120, NVP-BKM120) purchased from Selleck.

    After starved in serum-free medium for 24 h,A549 cells incubated with the indicated concentrations of BKM120 for 3 h,followed by 20-minute stimolation of 100ng/ml EGF.

    Dr. Zhang of Tianjin Medical University. Buparlisib (BKM120, NVP-BKM120) purchased from Selleck.

  • One customer. Buparlisib (BKM120, NVP-BKM120) purchased from Selleck.

    Dr. Pilar Eroles of INCLIVA Biomedical Research Institute.. Buparlisib (BKM120, NVP-BKM120) purchased from Selleck.

产品安全说明书

PI3K抑制剂选择性比较

生物活性

产品描述 Buparlisib (BKM120, NVP-BKM120) 是一种选择性 PI3K 抑制剂,在无细胞试验中作用于p110α/β/δ/γIC50分别为 52 nM/166 nM/116 nM/262 nM。对 VPS34,mTOR,DNAPK 的作用效果下降,而对 PI4Kβ几乎没有活性。Phase 2。
特性 BKM120是可用于口服的生物有效的PI3K抑制剂。
靶点
p110α [1]
(Cell-free assay)
p110δ [1]
(Cell-free assay)
p110β [1]
(Cell-free assay)
p110γ [1]
(Cell-free assay)
Vps34 [1]
(Cell-free assay)
52 nM 116 nM 166 nM 262 nM 2.4 μM
体外研究

BKM120作用于解除PI3K调节的细胞系,包括A2780, U87MG, MCF7和DU145时,具有抗增殖活性,GI50为0.1-0.7 nM。[1] BKM120诱导多发性骨髓瘤细胞(ARP1, ARK, MM.1S, MM1.R和U266)凋亡,导致G1期细胞增多,S期细胞减少。BKM120诱导CD138+原代MM 细胞凋亡,且作用于CD138−基质细胞时毒性较低。BKM120可引起BimS的上调和XIAP的下调。[2]BKM120作用于人类胃癌细胞系,降低mTOR下游信号,具有抗增殖活性。BKM120作用于KRAS突变的胃癌细胞系,可以增强p-ERK或 p-STAT3。BKM120 和STAT3阻断剂联用, 作用于含突变KRAS的细胞,诱导凋亡,具有协同效应,但是作用于KRAS野生型细胞没有这种效果。[3]BKM120主要通过Aurora B激酶调节有丝分裂崩坏。[4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MCF7 NGfuVopEgXSxdH;4bYMhSXO|YYm= NV33WJpEPzJiaB?= NVPOSmhtTE2VTx?= MYHDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJIV5eHKnc4PpcochWEl|S3HsdIhiKEV3NEXLJI12fGGwdDD3bZRpKEeLNUCgc4YhOC5yMECxOVgh|ryP M1LwNlI1QTByMk[2
DU145 MmrpR5l1d3SxeHnjJGF{e2G7 M333NVczKGh? M2D0TWROW09? M4nzTWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGRWOTR3IHPlcIx{KGW6cILld5NqdmdiTFvCNUBufXSjboSge4l1cCCJSUWwJI9nKDBwMECwOFM2KM7:TR?= MXiyOFkxODJ4Nh?=
A2780 M3XyR2N6fG:2b4jpZ{BCe3OjeR?= MlHYO|IhcA>? M2CwXWROW09? M2PxcGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KFCWRV6t[IVncWOrZX70JIh2dWGwIFGyO|gxKGOnbHzzJJdqfGhiR1m1NEBw\iByLkCwNFY{PSEQvF2= MVuyOFkxODJ4Nh?=
U87MG NH\Zb5pEgXSxdH;4bYMhSXO|YYm= NGj3OVg4OiCq M{fHfWROW09? MnzUR5l1d3SxeHnjbZR6KGGpYXnud5QhWFSHTj3k[YZq[2mnboSgbJVu[W5iVUi3UWch[2WubIOge4l1cCCJSUWwJI9nKDBwMECwOlk5KM7:TR?= M{L3cVI1QTByMk[2
A2780 NWPSTVZGTnWwY4Tpc44hSXO|YYm= Mn\YNUBp NUL3fXl[TE2VTx?= NUXodFJDUW6qaXLpeIlwdiCxZjDQTVNMNW2nZHnheIVlKEGNVDDT[ZI1PzNicHjvd5Bpd3K7bHH0bY9vKHerdHigSWM2OCCxZjCwMlA2PSEQvF2= MXyyOFkxODJ4Nh?=
DU145 M4LmUmZ2dmO2aX;uJGF{e2G7 MWexJIg> MYTEUXNQ Moi0TY5pcWKrdHnvckBw\iCSSUPLMY1m\GmjdHXkJGFMXCCVZYK0O|MheGixc4Doc5J6dGG2aX;uJIlvKGi3bXHuJGRWOTR3IHPlcIx{KGijcnLvdolv\yCOS1KxJI12fGG2aX;uJJdqfGhiRVO1NEBw\iByLkC3N{DPxE1? M1u0VlI1QTByMk[2
A2780 Mn\VSpVv[3Srb36gRZN{[Xl? NULOS4lmOSCq M3TFd2ROW09? MXfJcohq[mm2aX;uJI9nKFCLM1utcYVlcWG2ZXSgRWtVKFOnckS3N{BxcG:|cHjvdplt[XSrb36gbY4hWFSHTj3k[YZq[2mnboSgbJVu[W5iQUK3PFAh[2WubIOge4l1cCCHQ{WwJI9nKDBwMEe0JO69VQ>? M4n6VFI1QTByMk[2
MCF7 MkTISpVv[3Srb36gRZN{[Xl? M{PCSVEhcA>? MmfPSG1UVw>? MmPwTY5pcWKrdHnvckBw\iCSSUPLZYxxcGFiRUW0OWshdXW2YX70MY1m\GmjdHXkJGFMXCCVZYK0O|MheGixc4Doc5J6dGG2aX;uJJdqfGhiRVO1NEBw\iByLkGg{txO NXjR[WVDOjR7MECyOlY>
U87MG NX;lSIdETnWwY4Tpc44hSXO|YYm= NUDmN2s{OSCq MX3EUXNQ MWPJcohq[mm2aX;uJI9nKFCLM1utcYVlcWG2ZXSgRWtVKFOnckS3N{BxcG:|cHjvdplt[XSrb36gbY4hWFSHTj3k[YZq[2mnboSgbJVu[W5iVUi3UWch[2WubIOge4l1cCCHQ{WwJI9nKDBwMUOg{txO MX6yOFkxODJ4Nh?=
A2780 MnX3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVnHVVV[PzJiaB?= MYfEUXNQ NVn5U2tITUN3ME2wMlUzKM7:TR?= NGDMPYQzPDlyMEK2Oi=>
SKMES-1 MWfDfZRwfG:6aXOgRZN{[Xl? MV2xJO69VQ>? NXexbZVNPzJiaB?= NIDNcG9KdmS3Y3XzJINmdGxiZHXheIg> Ml;NNlYxOTN|MUi=
H596 NW\zRlJPTnWwY4Tpc44hSXO|YYm= MYSxJO69VQ>? MUDJcZBicXK|IHPlcIwhdWmpcnH0bY9v NFn4XY8zPjBzM{OxPC=>
HCC2450 NF3rXmpHfW6ldHnvckBCe3OjeR?= M3X6TlEh|ryP NF[2N|FKdXCjaYLzJINmdGxiaX72ZZNqd25? NVXWSHQ6OjZyMUOzNVg>
A549 Mn3xSpVv[3Srb36gRZN{[Xl? MVq1NFAhdk1? M12yd|Q5KGh? MlTvSG1UVw>? Mlm3TY5pcWKrdIOgRYt1KGGldHn2ZZRqd25? M3XRVVI2QTN5Mkm5
A549 M4Pab2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUWxJO69VQ>? MXO3NkBp NYHOSmFiTE2VTx?= MnXrTY5pcWKrdIOgZ4VtdCCpcn;3eIg> M1LWW|I2QTN5Mkm5
H522 MljpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYGxJO69VQ>? MVW3NkBp M1\k[GROW09? MYnJcohq[mm2czDj[YxtKGe{b4f0bC=> NXrTR|N5OjV7M{eyPVk>
LNCaP MlriSpVv[3Srb36gRZN{[Xl? NVnZToJROSEQvF2= MnLvV5VxeHKnc4Pld{BxNUGNVDDs[ZZmdHN? NEnL[HozPTN4MEe5PS=>
LNCaP95 MUXGeY5kfGmxbjDBd5NigQ>? M3LkdFEh|ryP Mn7qV5VxeHKnc4Pld{BxNUGNVDDs[ZZmdHN? NFrjPJEzPTN4MEe5PS=>
HCT-15 M1HZOmFxd3Sxc3nzJGF{e2G7 NWj5SJU2OTBizszN NUHJUGw5PDhiaB?= NWjhSpZKTE2VTx?= NGPMflJKdmS3Y3XzJIFxd3C2b4Ppd{BqdiCKQ2StNVUh[2WubIOgbIFz[m:3cnnu[{BRUUt|Q1GgbI91e3CxdDDteZRifGmxbh?= NYfnWIkxOjVzNUKyOFU>
HCT-116 MWTBdI91d3OrczDBd5NigQ>? Mn21NVAh|ryP M4C2V|Q5KGh? MYHEUXNQ M3v2Umlv\HWlZYOgZZBweHSxc3nzJIlvKEiFVD2xNVYh[2WubIOgbIFz[m:3cnnu[{BRUUt|Q1GgbI91e3CxdDDteZRifGmxbh?= M1u2OlI2OTV{MkS1
NCI-H460 NX;ybohESXCxdH;zbZMhSXO|YYm= NIi3XYYyOCEQvF2= NX3DWGt4PDhiaB?= NVW2T|hPTE2VTx?= M3:zfGlv\HWlZYOgZZBweHSxc3nzJIlvKE6FST3IOFYxKGOnbHzzJIhiemKxdYLpcochWEmNM1PBJIhwfHOyb4SgcZV1[XSrb36= M2LpU|I2OTV{MkS1
SKOV-3 MVXBdI91d3OrczDBd5NigQ>? NEnuO2MyOCEQvF2= MWq0PEBp M2myZWROW09? NWrXSlVbUW6mdXPld{BieG:ydH;zbZMhcW5iU1vPWk0{KGOnbHzzJIhiemKxdYLpcochWEmNM1PBJIhwfHOyb4SgcZV1[XSrb36= M{DSW|I2OTV{MkS1
BSY-1 M{nK[mFxd3Sxc3nzJGF{e2G7 NVz1ToVHOTBizszN NIDzeVI1QCCq NYnBNIxyTE2VTx?= MmTUTY5lfWOnczDhdI9xfG:|aYOgbY4hSlO\LUGgZ4VtdHNiaHHyZo92emmwZzDQTWs{S0FiaH;0d5BwfCCvdYTheIlwdg>? MVSyOVE2OjJ2NR?=
MKN-1 MXvBdI91d3OrczDBd5NigQ>? M4HYNFExKM7:TR?= M1j0[lQ5KGh? NWLLPVl2TE2VTx?= MmrvTY5lfWOnczDhdI9xfG:|aYOgbY4hVUuQLUGgZ4VtdHNiaHHyZo92emmwZzDQTWs{S0FiaH;0d5BwfCCvdYTheIlwdg>? NUXPSmJ4OjVzNUKyOFU>
NCI-H522 MmKwRZBwfG:|aYOgRZN{[Xl? MkHhNVAh|ryP M162ZVQ5KGh? NEjpV4NFVVOR NE\EVZlKdmS3Y3XzJIFxd3C2b4Ppdy=> NX33WJp[OjVzNUKyOFU>
OVCAR-3 MlTVRZBwfG:|aYOgRZN{[Xl? NX7EN4xSOTBizszN M1vsTFQ5KGh? NFS0R4JFVVOR NID4bFBKdmS3Y3XzJIFxd3C2b4Ppdy=> NIraO5UzPTF3MkK0OS=>
HBC-5 NIHmT5pCeG:2b4Ppd{BCe3OjeR?= MlnPNVAh|ryP NHnBb3Q1QCCq MY\EUXNQ MVvJcoR2[2W|IHHwc5B1d3Orcx?= M3TLW|I2OTV{MkS1
RXF-631L M3vpT2Fxd3Sxc3nzJGF{e2G7 M4DHR|ExKM7:TR?= NIrkN3M1QCCq MlHISG1UVw>? MWfJcoR2[2W|IHHwc5B1d3Orcx?= NYPQVGNrOjVzNUKyOFU>
MKN-45 MYHBdI91d3OrczDBd5NigQ>? NXrZcFd6OTBizszN MVm0PEBp Mn[xSG1UVw>? MXrJcoR2[2W|IHHwc5B1d3Orcx?= NWL3WFJSOjVzNUKyOFU>
BON-1 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\ONpA2ODBibl2= NEPsfIcyOCCm MmjiSG1UVw>? MkXUTY5pcWKrdIOgZ4VtdCCpcn;3eIg> M1X5WlI2ODJ4Mkmy
BON-1 NFLVbpFHfW6ldHnvckBCe3OjeR?= NYXFTZdSPTByIH7N MXi0JIg> NGfXZ5pFVVOR NXnlRlFFUW6qaXLpeJMheGixc4Doc5J6dGG2aX;uJI9nKEGNVDDheEBVcHJ|MEigZY5lKFOnckS3Ny=> NXzjbodXOjVyMk[yPVI>
QGP-1 MW\GeY5kfGmxbjDBd5NigQ>? NUPqeGFsPTByIH7N M2TVflQhcA>? NH7kb4tFVVOR MoLCTY5pcWKrdIOgdIhwe3Cqb4L5cIF1cW:wIH;mJGFMXCCjdDDUbJI{ODhiYX7kJHNmejR5Mx?= MnvFNlUxOjZ{OUK=
Huh7 NHTV[YRHfW6ldHnvckBCe3OjeR?= NH\ITHQyKM7:TR?= MUmxJIg> Mo\nSG1UVw>? M1rHe2lvcGmkaYTzJJBpd3OyaH;yfYxifGmxbjDv[kBCU1RiYYSgV4VzPDd2 NXTY[2ZlOjVyMES0NFM>
BNL NUj4NpV7TnWwY4Tpc44hSXO|YYm= MYKxJO69VQ>? MoXjNUBp MnHkSG1UVw>? M{DadmlvcGmkaYTzJJBpd3OyaH;yfYxifGmxbjDv[kBUPg>? NGXxfYgzPTByNESwNy=>
MDA-MB-175 NFK5XlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1jjPVEh|ryP MkLEOUBl M4[xRWROW09? NHTpfYJKSzVyPEGg{txO NIixTG0zPDh5OUe5Oi=>
MDA-MB-134 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHTkcZkyKM7:TR?= NE\EU4U2KGR? NYLKUmtvTE2VTx?= M1Lp[2lEPTB:MTFOwG0> NFzzS2UzPDh5OUe5Oi=>
HCC1500 M{PzVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmG3NUDPxE1? MVe1JIQ> MkXzSG1UVw>? NIWyR2NKSzVyPEGg{txO MmP1NlQ5Pzl5OU[=
EFM-19 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXSxJO69VQ>? NUjF[5ZZPSCm NGr0Z3hFVVOR M4O0TWlEPTB:MTFOwG0> NXLrW2t2OjR6N{m3PVY>
ZR-75-30 M3zRPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NInJXJEyKM7:TR?= NF;KZ242KGR? NETkWGxFVVOR MmTZTWM2ODxzIN88US=> MnfSNlQ5Pzl5OU[=
MDA-MB-361 NGjqd2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2f5[lEh|ryP M13lSVUh\A>? NVrod|l2TE2VTx?= MXnJR|UxRDFizszN Ml\INlQ5Pzl5OU[=
T-47D NV3uc4E3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlTpNUDPxE1? MYK1JIQ> NWezOmRGTE2VTx?= MlP1TWM2ODxzIN88US=> MWOyOFg4QTd7Nh?=
SK-BR-3 NF[xPXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{XhVlEh|ryP NFPJO282KGR? MkntSG1UVw>? M4PQfWlEPTB:MTFOwG0> M1jpWFI1QDd7N{m2
UACC-732 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\LNUDPxE1? MnfzOUBl NEnRS2hFVVOR Mnf4TWM2ODxzIN88US=> MUKyOFg4QTd7Nh?=
BT-474 NFmzcJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1rPZ|Eh|ryP NVz2WWxRPSCm NUHtR|lITE2VTx?= MULJR|UxRDFizszN NUK0W4dMOjR6N{m3PVY>
HCC202 Mn\yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{j0blEh|ryP MV61JIQ> NUXKRWJXTE2VTx?= MYDJR|UxRDFizszN NWnCSVl7OjR6N{m3PVY>
MCF7 M3nYfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{LJZ|Eh|ryP MXq1JIQ> M1rKfGROW09? MoH2TWM2ODxzIN88US=> NXrmdXhoOjR6N{m3PVY>
MDA-MB-415 NW\lfWV[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmG0NUDPxE1? MoezOUBl M1fBTmROW09? NX7tOFJ7UUN3MEyxJO69VQ>? M2\je|I1QDd7N{m2
MDA-MB-453 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHu4SW0yKM7:TR?= M2Sz[VUh\A>? MmnoSG1UVw>? MlXLTWM2ODxzIN88US=> NHz5UY8zPDh5OUe5Oi=>
ZR-75-1 MnzBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlHxNUDPxE1? MoriOUBl M4TMRmROW09? MYPJR|UxRDFizszN MWWyOFg4QTd7Nh?=
HCC38 NXrtb|dZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWPOWpU{OSEQvF2= MojiOUBl MkD0SG1UVw>? MUPJR|UxRDFizszN M3ThOFI1QDd7N{m2
HCC1419 NXz0d495T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnTlNUDPxE1? NXnkPWFKPSCm M1XBUGROW09? NIPjcFVKSzVyPEGg{txO MUiyOFg4QTd7Nh?=
UACC-812 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV3hOpA3OSEQvF2= NFfqeXY2KGR? MkTOSG1UVw>? NWX6SW42UUN3MEyxJO69VQ>? MXyyOFg4QTd7Nh?=
HCC1187 MmT2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHjxNm0yKM7:TR?= NYLEOVdpPSCm MmrtSG1UVw>? MkO1TWM2ODxzIN88US=> MVGyOFg4QTd7Nh?=
KPL-1 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlm3NUDPxE1? NX7uVnY5PSCm MXrEUXNQ NVHBSnRQUUN3MEyxJO69VQ>? NEXUN4MzPDh5OUe5Oi=>
SUM-225 M1H6dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mon4NUDPxE1? MXO1JIQ> M1\XfWROW09? NG\HeGxKSzVyPEGg{txO MWmyOFg4QTd7Nh?=
EFM-192A MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2LBclEh|ryP NYH1T24zPSCm NFrhN2hFVVOR NEDZbXJKSzVyPEGg{txO M3:zXFI1QDd7N{m2
JIMT-1 MnfXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn75NUDPxE1? NHW5cG42KGR? Mlf1SG1UVw>? M3jMbmlEPTB:MTFOwG0> MmfmNlQ5Pzl5OU[=
HCC1143 NYPsR3k6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWKxJO69VQ>? NG\S[Go2KGR? M1nPSmROW09? M4n1N2lEPTB:MTFOwG0> NVfjNZpxOjR6N{m3PVY>
HCC2218 M1HkNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWTBXpVxOSEQvF2= MWq1JIQ> M3fVUmROW09? NV3vbXNqUUN3MEyxJO69VQ>? MW[yOFg4QTd7Nh?=
MDA-MB-468 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4qzRlEh|ryP MWW1JIQ> MX7EUXNQ NFjG[lRKSzVyPEGg{txO MlPjNlQ5Pzl5OU[=
BT-20 M4rYS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\yXmh4OSEQvF2= Ml74OUBl MkG1SG1UVw>? NUHGSVEzUUN3MEyxJO69VQ>? M2TmW|I1QDd7N{m2
MDA-MB-435 MojsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jSN|Eh|ryP M{nyN|Uh\A>? NHzPb|hFVVOR NV\kUGc1UUN3MEyxJO69VQ>? M4XWZ|I1QDd7N{m2
BT-549 NFzqV2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXWwXpJwOSEQvF2= MXq1JIQ> NWfaRVFQTE2VTx?= M3z2U2lEPTB:MTFOwG0> NW\Ic4dKOjR6N{m3PVY>
HCC1806 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWT3SFNTOSEQvF2= NXzuZoVZPSCm NHrTNYxFVVOR MWrJR|UxRDFizszN Ml\1NlQ5Pzl5OU[=
HCC1937 NUPuO2gyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkTBNUDPxE1? NUTxWpVJPSCm MW\EUXNQ NX75cpNlUUN3MEyxJO69VQ>? Mn7wNlQ5Pzl5OU[=
Hs578T NVrhV3k4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULjV2pMOSEQvF2= NGP2UYg2KGR? MVTEUXNQ NU\1bnhzUUN3MEyxJO69VQ>? MUOyOFg4QTd7Nh?=
LN18 M2XRfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvWV3czOCEQvF2= NVvDWGlZPzJiaB?= Mom5SG1UVw>? NUC3N2FjUUN3MEy1JO69VQ>? NXLEZZhPOjR5NEGwO|Q>
LN229 NYHlO|g5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVOyNEDPxE1? NXXS[pFIPzJiaB?= NULNXIpuTE2VTx?= MUTJR|UxRDVizszN MUKyOFc1OTB5NB?=
LNZ308 NV;KcmtjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkjJNlAh|ryP MlTTO|IhcA>? MkiySG1UVw>? NF3p[ZRKSzVyPEWg{txO MXmyOFc1OTB5NB?=
T98G NX\ySpBKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWnxc|ZKOjBizszN NIKwN|E4OiCq MlzCSG1UVw>? Mn;STWM2ODx3IN88US=> NWnDZ3diOjR5NEGwO|Q>
U87 NXr0WoV7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnX3NlAh|ryP NEXZSoU4OiCq MUHEUXNQ MlftTWM2ODx3IN88US=> NFPRSXAzPDd2MUC3OC=>
LN18 MlTFSpVv[3Srb36gRZN{[Xl? NVzqWHZvPSEQvF2= MUSyOEBp NILYUGFFVVOR Mn\qTY5pcWKrdIOgdIhwe3Cqb4L5cIF1cW:wIH;mJGFMXA>? NXjZVoxyOjR5NEGwO|Q>
LNZ308 Mn\PSpVv[3Srb36gRZN{[Xl? M1j0UFUh|ryP MXmyOEBp MVnEUXNQ NH7MPGtKdmirYnn0d{BxcG:|cHjvdplt[XSrb36gc4YhSUuW M{L4UFI1PzRzMEe0
Saos-2 NIrEc|ZHfW6ldHnvckBCe3OjeR?= MnXMOVAh|ryP Moe2OFghcA>? M1vVe2lvcGmkaYTzJINmdGxiaX72ZZNqd25? NW[1SYM{OjR5Mke2OlA>
MG-63 M2D2ZWZ2dmO2aX;uJGF{e2G7 Mn7MOVAh|ryP NH2zU3A1QCCq MnTtTY5pcWKrdIOgZ4VtdCCrbo\hd4lwdg>? NVjobFBzOjR5Mke2OlA>
SJSA-1 MnrMSpVv[3Srb36gRZN{[Xl? NXfZUo5{PTBizszN M4\oUVQ5KGh? MYPJcohq[mm2czDj[YxtKGmwdnHzbY9v M3vHT|I1PzJ5Nk[w
Saos-2 NF;vW2FHfW6ldHnvckBCe3OjeR?= NGDy[IY2OCEQvF2= NEnjUGw1QCCq MUfJcohq[mm2czDtZZRzcXhibXX0ZYxtd3C{b4TlbY5ie2VvMjDlfJBz\XO|aX;u NUPMdIE{OjR5Mke2OlA>
MG-63 M332bmZ2dmO2aX;uJGF{e2G7 MmXLOVAh|ryP NY\x[Gw5PDhiaB?= NVjSZY1iUW6qaXLpeJMhdWG2cnn4JI1mfGGubH;wdo91\WmwYYPlMVIh\XiycnXzd4lwdg>? NHvqXVMzPDd{N{[2NC=>
SJSA-1 Mn6ySpVv[3Srb36gRZN{[Xl? NW[xN5pSPTBizszN MV20PEBp NFfIfFhKdmirYnn0d{Bu[XS{aYigcYV1[Wyub4Dyc5RmcW6jc3WtNkBmgHC{ZYPzbY9v MnLSNlQ4Ojd4NkC=
Saos-2 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYi1NEDPxE1? M3ryOFQ5KGh? Mn3lTY5pcWKrdIOgZ4VtdCC4aXHibYxqfHl? NGDkdGMzPDd{N{[2NC=>
MG-63 NELvZWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFj2V2c2OCEQvF2= MYC0PEBp NF;DW3VKdmirYnn0d{Bk\WyuII\pZYJqdGm2eR?= NXzJ[W9KOjR5Mke2OlA>
SJSA-1 M{DmTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIXsWmM2OCEQvF2= NXW3THNXPDhiaB?= NHH4dY9KdmirYnn0d{Bk\WyuII\pZYJqdGm2eR?= NGjzW5AzPDd{N{[2NC=>
FaDu M4ruS2Z2dmO2aX;uJGF{e2G7 NHi0fok2KM7:TR?= NIfkeJUzPCCq MoX5SG1UVw>? Ml7jVoVlfWOnczDvfJlo\W5iY3;ud5VueHSrb36= MW[yOFY{OTF2Nx?=
EMT6 NWXOO3N{TnWwY4Tpc44hSXO|YYm= M17XZ|Uh|ryP MnfHNlQhcA>? NWfhVXFbTE2VTx?= M3PObHJm\HWlZYOgc5h6\2WwIHPvcpN2dXC2aX;u NYfsdJNtOjR4M{GxOFc>
HCT116 NHewRXRHfW6ldHnvckBCe3OjeR?= NELUT3I2KM7:TR?= NV;iXVZsOjRiaB?= MUTEUXNQ MVjS[YR2[2W|IH;4fYdmdiClb37zeY1xfGmxbh?= NHK4VHYzPDZ|MUG0Oy=>
U87 Mn\sSpVv[3Srb36gRZN{[Xl? NFrET2s2KM7:TR?= NVLnUmVMOjRiaB?= MUXEUXNQ NXzuO2pNWmWmdXPld{BwgHmpZX6gZ49ve3WvcITpc44> M2Gz[VI1PjNzMUS3
GBM NIqzVW1CeG:ydH;zbZMhSXO|YYm= NIrYOXgz|ryP MkjYOFhp M13lRmROW09? MmnubY5lfWOnZDDobYdp\XJibHX2[Yx{KG:oIHHwc5B1d3OrczygZY5lKGSnY4LlZZNm\CClZXzsJJZq[WKrbHn0fS=> NFO1Ro4zPDVyMES5Ni=>
BON MoHnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXqxMVXPxE1? MoDhO|Jp NIKyN5hl\WO{ZXHz[ZMh[2WubDDwdo9tcW[ncnH0bY9v MWqyOFQ1OzV{Mx?=
BON MVrBdI9xfG:|aYOgRZN{[Xl? M3n6TVEuPc7:TR?= M2D2VlI1cA>? Ml;0bY5kemWjc3XzJIFxd3C2b4Ppdy=> NFPO[48zPDR2M{WyNy=>
H1975 NWKzZlZ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3Tjb|AvOy17LkdOwG0> M3KwXFczcA>? NGLqc3NFVVOR MUjJR|UxRTFwM{i1{txO M3jGVFI1OzN5OES2
H1975 MWHBdI9xfG:|aYOgRZN{[Xl? Mn\0Nu69VQ>? MmnWNlRp MnnYSG1UVw>? MX\pcoNz\WG|ZYOgZZBweHSxc3nzJJJifGVic3nncolncWOjboTsfS=> NV;aR5oyOjR|M{e4OFY>
T-ALL NXHxc5NkSXCxcITvd4l{KEG|c3H5 M3PheoJmfHenZX6gNU41KGGwZDC1MlMhdU1iYYSgNlRpKGGwZDCwMlkh[W6mIEWuOUBuVSCjdDC0PIghcW5iZHnm[oVz\W62IHPlcIwhdGmwZR?= MnjkNlQhd3JiNEjo NWT0UFd7TE2VTx?= MUPh[oZm[3S|IITo[UBRUTONIIDheIh4[XliaX6gWE1CVExiY3XscEBtcW6ncx?= NUL0V5hqOjR|MUC3N|Y>
BCR-ABL NUTNfVV1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\PWXIxNjJ3LUGw{txO NILSeII1\A>? Mmmzd4lodmmoaXPhcpRtgSCrbnjpZol1KGOnbHygdJJwdGmoZYLheIlwdg>? MV[yOFI1PDZzMh?=
LC-1/SQSF MnW3SpVv[3Srb36gRZN{[Xl? NXLKfVVNO87:TR?= MUWyOIg> M2joXmROW09? MoTG[IVkemWjc3WgUnJHOiCycn;0[YlvKGyndnXs NGjBOYwzOzl6MEC5Ny=>
Primary CLL cells MmjYRZBweHSxc3nzJGF{e2G7 MYOxMVEx|ryP MYC0PIg> MmjPbY5lfWOnczDhdI9xfG:|aYOgbY4hS0yOIHPlcIx{KGmwZHXw[Y5l\W62IH;mJJBzd2ewb4P0bYMhdWG{a3Xydy=> NEDaZ4IzOzh3MEiwOy=>
Primary CLL cells NUmyRnBEU2mwYYPlJGF{e2G7 NV3COHFrOs7:TR?= Ml7DN|BucW5? NUD6PZBT\GWlcnXhd4VlKFCLM1ugZYN1cX[rdIm= MoLRNlM5PTB6MEe=
Primary CLL cells M1K3VGN6fG:2b4jpZ{BCe3OjeR?= MmjKNu69VQ>? Mom4NlRp M2fsWIlv\HWlZYOgZ4VtdCCleYTveI95cWOrdIm= MkDMNlM5PTB6MEe=
human NSCLC cell lines M4XSPGFxd3C2b4Ppd{BCe3OjeR?= M{LBUlAvOTJ3LUVOwG0> MY[yOIg> M1f6O2ROW09? NX3peml{UUN3MIOgdoFv\2W|IH\yc40hOC52LUNOwG0> MmXaNlM2PjJ2N{K=
human HCC cell lines MlTMR4VtdCC4aXHibYxqfHliYYPzZZk> MWGwMlAxPS1zzszN NEnCblU1QGh? NWDncYJoUUN3ME2x{txO NGjHOmYzOzR6OUm5PS=>
Huh7 NWe2TGdbU2mwYYPlJGF{e2G7 MnHPNe69VQ>? M3TkS|Q5cA>? NIrFZmx{cWewaf-shYNidnSueTDy[YR2[2W|IIDoc5NxcG:{eXzheIlwdiCxZjDBb5Q> M4rjelI{PDh7OUm5
SK-HEP1 NEK3TWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\xWXYyNTJyzszN NYTpXGZbPzKq MX;EUXNQ MoXWTWM2OO,:nEJOwG0> NWTHNm5rOjN2N{mxN|Y>
786-0 M4exOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2rzNVEuOjEQvF2= MoPFO|Jp M3;WfWROW09? NIrKeGxKSzVy78{cNe69VQ>? NWXOeYw2OjN2N{mxN|Y>
JVM2 NUHTXnNtS3m2b4TvfIlkcXS7IHHzd4F6 NXXDTFlyOC5{LUKw{txO MlXCO|Jp M{DUPWROW09? NH;PTmRKSzVyPUCuPe69VQ>? NHjmNmozOzJ|OE[zPS=>
EHEB MUnDfZRwfG:6aXPpeJkh[XO|YYm= M4PwRlAvOi1{MN88US=> NFH5fFM4Omh? NWfCfI17TE2VTx?= MWfJR|UxRTBwN988US=> MUmyN|I{QDZ|OR?=
MEC2 NH3jXZREgXSxdH;4bYNqfHliYYPzZZk> NXzDZpZ[OC5{LUKw{txO NFLCd|I4Omh? NV3BRXc4TE2VTx?= MYfJR|UxRTBwN988US=> MWKyN|I{QDZ|OR?=
primary B-CLL lymphocytes MmnkRZBweHSxc3nzJGF{e2G7 MYrJR|UxKG[xcjDlZYNpKHC{aX3hdpkh[2WubDDsbY5m NV7yZpZsOjSq NHXrclRFVVOR M3izSWlEPTExvKyz{txOKG[xcjDhcIwheGG2aXXueJM> MljONlMzOzh4M{m=
primary B-CLL lymphocytes MnywT4lv[XOnIFHzd4F6 M33X[mlEPTBiZn;yJIVi[2hicILpcYFzgSClZXzsJIxqdmV? Mo\RNlRp M4TuZolvcGmkaYTzJJA4OFN4SzCmJFRGNUKSMTDlfJBz\XO|aX;u M1W4[FI{OjN6NkO5
human NSCLC MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlrnNE42NTMQvF2= NX:3blFrPzKq M32xWmlEPTB;Md88US=> M3XuSlIzPzhzM{mz
human NSCLC NF7LOmxMcW6jc3WgRZN{[Xl? MXux{txO NHHwW5UzPGh? M2\SVIlvcGmkaYTzJJRp\SCDa4SvcXRQWiC|aXfuZYxqdmdicHH0bJdigSCjdDCzbEBi\nSncjD0doVifG2nboS= NUfPN2pUOjJ5OEGzPVM>
Y1 cell line MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHWwXGoxNjIQvF2vNe69VQ>? M2jDRlI1cA>? MnrESG1UVw>? MlrwbY5pcWKrdIOgOlDwxIViY3XscEB3cWGkaXzpeJkhcW5iTYnjMXNkfHJvdILhcpNn\WO2ZXSgZ4VtdHN? NWfl[5VzOjJ4OUK5NFQ>
PIK3CA-mutant MCF7 MmjDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPnVoV2T0l3ME2xOlDDuTlzbl5vwKxNTDVyPUm4NOKyOjd|bl2= M3[5blczcA>? MlrxS2k2OD1zNkFCtVkydk4xvJzMSFUxRTl6MNMxNlc{dk1? M3O0XFIzPjV|OU[3
PIK3CA-mutant MCF7 M2i2XWtqdmG|ZTDBd5NigQ>? NXrFV3FsUUN3ME2xNVTDuTOwTR?= NY\1TY9IPzKq Mm\ETWM2OD1zMUVCtVNvVSCrbjDy[YR2[2mwZzDBb5QheGixc4Doc5J6dGG2aX;uJIxmfmWucx?= M3zLV|IzPjV|OU[3
MCF7-myr-Akt NWPZU3MzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWXrXXNvT0l3ME2yPVnDuTZ6bl5vwKxNTDVy78{eNVAtODBybl2= MUS3Nog> NWq0[3NWT0l3ME2yPVnDuTZ6bl5vwKxNTDVy78{eNVAtODBybl2= NXnqSFdGOjJ4NUO5Olc>
colon cancer cell lines MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUmwMVEx|ryP NGTMUGI4Omh? NF3DRWhFVVOR MnfjTWM2OD1zzszN MWWyNlU1Ozh3Nx?=
gastric cancer cell lines MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXLDSoUzOC1zMN88US=> MVO3Nog> MnvPSG1UVw>? MmO0TWM2OD1{LUZOwG0> NH7ZOYwzOjV2M{i1Oy=>
HCT-116/HT-29/MKN-45 NHriepdCeG:ydH;zbZMhSXO|YYm= MmnXNu69VQ>? NFPyVJo1QGh? Mnnrd4hq\nRiaX6gS|IheGijc3W= M4HnRlIzPTR|OEW3
HT-29 and HCT-116 M1PqfWNie3Cjc3WgZZN{[Xl? NEXTTlU2|ryP NHjUdI4zPGh? MorObY5lfWOnczDjZZNx[XOnIHHjeIl3cXS7 MkTONlI2PDN6NUe=
MM cell lines MmO2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml74NVDPxE1? NYXrcIlZOjSq M4LZfGROW09? M{TUSmlEPTBidnHybYV{KGGvb37nJIRq\m[ncnXueEBk\WyuIHzpcoV{KGmwIITpcYUh[W6mIHTvd4Uh\GWyZX7k[Y5k\Q>? NWnSNFN{OjJ{MEe0PFU>
ARP-1 NGe0eXBCeG:ydH;zbZMhSXO|YYm= Mn\lNVDPxE1? MViyOIg> NGjnOmlFVVOR Ml7HbY5lfWOnczDNUUBk\WyuIHHwc5B1d3OrczD0bJJwfWeqIHPhd5Bie2ViYXP0bZZifGmxbh?= NIPrbWwzOjJyN{S4OS=>
SNU-601 M3\qXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmLSO|Jp M4nPO2ROW09? MkTuTWM2OD1yLkixOuKyOC5yNkROwG0> M2nTdlIzOTV7OEG0
SNU-1 NFHie25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mme3O|Jp MUDEUXNQ M4rTUGlEPTB;MT6wPFLDuTBwMEK4{txO NXnyfWt2OjJzNUm4NVQ>
SNU-668 M1;nZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn31O|Jp MX7EUXNQ M4ryOGlEPTB;MT61O|nDuTBwMEe0{txO NX:xU2dsOjJzNUm4NVQ>
AGS MmLtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVm5OGo3PzKq MWPEUXNQ NW\RfZlmUUN3ME2xMlcyPMLzMD6xNVfPxE1? M3HKOVIzOTV7OEG0
SNU-216 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX63WGtYPzKq NInSPHdFVVOR NED4[GhKSzVyPUKuOlkzyrFyLkC4Nu69VQ>? M1WyVVIzOTV7OEG0
SNU-5 NFTq[GRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV63Nog> M4DpXmROW09? Ml\FTWM2OD1zLkO1NeKyOC5yOUJOwG0> NWL2eXZsOjJzNUm4NVQ>
SNU-638 M4nwbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\6T3RVPzKq NV\0fGdiTE2VTx?= NI[3d45KSzVyPUKuNlgzyrFyLkC1N:69VQ>? NIXHS5YzOjF3OUixOC=>
SNU-16 NFTIR5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHzdYV3PzKq NWLreXA2TE2VTx?= MWfJR|UxRTFwNUezxtExNjByMd88US=> NH3mZlczOjF3OUixOC=>
SNU-484 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\ZSFczcA>? MXnEUXNQ MXHJR|UxRTFwN{K4xtExNjB2Nd88US=> NImyToQzOjF3OUixOC=>
SNU-620 NIPNUnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlnWO|Jp M1e4bWROW09? MmD1TWM2OD1{LkmzPeKyOC5yMEJOwG0> NUDJZmlROjJzNUm4NVQ>
SNU-719 NXfxb2puT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M13z[VczcA>? M{DuTGROW09? NYLNTZNEUUN3ME2zMlA{P8LzMD6wN|LPxE1? M3zTclIzOTV7OEG0
glioma cell lines MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYK3Nog> NFH2b4xKSzVyPUGtNu69VQ>? MWWyNlA3PTB6MB?=
U87 NYLqUIFlSXCxcITvd4l{KEG|c3H5 MUOy{txO MVi3Nog> NELzfJFqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHHu[EBkdGWjdnXkJHBCWlBiYX7kJINie3Cjc3WtNy=> M4\OO|IzODZ3MEiw

... Click to View More Cell Line Experimental Data

体内研究 BKM120按30, 60, 或100 mg/kg剂量作用于A2780移植瘤,完全抑制pAKTser473。BKM120按 30和 60 mg/kg剂量作用于U87MG神经胶质瘤模型,显示抗癌活性。[1]BKM120每天按5μM/kg剂量处理具有持久生命力的ARP1 SCID鼠模型,导致肿瘤体积和K链水平明显降低。[2]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:[2]
+ 展开

PI3K 生化实验(ATP 消耗实验):

BKM120溶于DMSO中,按每孔1.25 µL直接加到黑色384孔板上。开始反应, 25 µL 10nM PI3K和5 µg/mL 1-α-磷酸肌醇(PI)加到实验 buffer (10 mM Tris pH 为7.5, 5 mM MgCl2, 20 mM NaCl, 1 mM DTT,及0.05% CHAPS),然后加到每孔中,随后在实验buffer中加入25 µL 2 µM ATP。反应进行直到50% ATP被消耗,然后加入25 µL KinaseGlo溶液终止反应。终止的反应温育5分钟,然后通过荧光测定残留的ATP。
细胞实验:[1]
+ 展开
  • Cell lines: A2780细 胞
  • Concentrations: 0-6.6 μM
  • Incubation Time: 3天
  • Method: A2780细胞培养在含10% FBS,L-谷氨酸,丙酮酸钠和抗生素的DMEM培养基上。细胞按每孔103个细胞的密度接种在相同培养基上,温育3到5小时。稀释溶于20 mM DMSO中的BKM120。2 µL稀释的BKM120溶液加到细胞培养基上, (浓度为0-6.6 µM)。等体积(100 µL)溶液加到96孔板中,在37oC下温育3天。使用Trilux读取荧光值而测定抑制细胞增殖的效果
    (Only for Reference)
动物实验:[1]
+ 展开
  • Animal Models: 携带U87MG 和A2780移植瘤的雌性裸鼠
  • Formulation: 15% Captisol
  • Dosages: ~60 mg/kg
  • Administration: 每天口服处理
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 82 mg/mL (199.8 mM)
Ethanol 2 mg/mL (4.87 mM)
Water Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
5% DMSO+30% PEG 300+ddH2O
15mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 410.39
化学式

C18H21F3N6O2

CAS号 944396-07-0
稳定性 powder
in solvent
别名 N/A

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01870726 Terminated c-MET Inhibitor; PI3K Inhibitor PTEN Mutations Homozygous Del. of PTEN or PTEN Neg. by IHC c-Met Ampli. by FISH INC280 BKM120 Buparlisib; Recurrent GBM Novartis Pharmaceuticals|Novartis January 9 2014 Phase 1|Phase 2
NCT01512251 Completed BRAF Mutant Metastatic Melanoma University of California San Francisco|Novartis June 9 2012 Phase 1|Phase 2
NCT01610284 Active not recruiting Breast Cancer Novartis Pharmaceuticals|Novartis August 7 2012 Phase 3
NCT02058381 Active not recruiting Pre-menopausal Breast Cancer|PI3K Pathway Inhibition Novartis Pharmaceuticals|Novartis May 6 2014 Phase 1
NCT02340780 Active not recruiting Chronic Lymphocytic Leukemia Canadian Cancer Trials Group|Novartis January 30 2015 Phase 2
NCT01473901 Completed Glioblastoma Novartis Pharmaceuticals|Novartis December 30 2011 Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

相关PI3K产品

Tags: 购买Buparlisib (BKM120, NVP-BKM120) | Buparlisib (BKM120, NVP-BKM120)供应商 | 采购Buparlisib (BKM120, NVP-BKM120) | Buparlisib (BKM120, NVP-BKM120)价格 | Buparlisib (BKM120, NVP-BKM120)生产 | 订购Buparlisib (BKM120, NVP-BKM120) | Buparlisib (BKM120, NVP-BKM120)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID